Literature DB >> 10649495

Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease.

D L Stone1, N Tayebi, E Orvisky, B Stubblefield, V Madike, E Sidransky.   

Abstract

Gaucher disease, the most common lysosomal storage disorder, results from the inherited deficiency of the enzyme glucocerebrosidase. Three clinical types are recognized: type 1, non-neuronopathic; type 2, acute neuronopathic; and type 3, subacute neuronopathic. Type 2 Gaucher disease, the rarest type, is progressive and fatal. We have performed molecular analyses of a cohort of 31 patients with type 2 Gaucher disease. The cases studied included fetuses presenting prenatally with hydrops fetalis, infants with the collodion baby phenotype, and infants diagnosed after several months of life. All 62 mutant glucocerebrosidase (GBA) alleles were identified. Thirty-three different mutant alleles were found, including point mutations, splice junction mutations, deletions, fusion alleles and recombinant alleles. Eleven novel mutations were identified in these patients: R131L, H255Q, R285H, S196P, H311R, c.330delA, V398F, F259L, c.533delC, Y304C and A190E. Mutation L444P was found on 25 patient alleles. Southern blots and direct sequencing demonstrated that mutation L444P occurred alone on 9 alleles, with E326K on one allele and as part of a recombinant allele on 15 alleles. There were no homozygotes for point mutation L444P. The recombinant alleles that included L444P resulted from either reciprocal recombination or gene conversion with the nearby glucocerebrosidase pseudogene, and seven different sites of recombination were identified. Homozygosity for a recombinant allele was associated with early lethality. We have also summarized the literature describing mutations associated with type 2 disease, and list 50 different mutations. This report constitutes the most comprehensive molecular study to date of type 2 Gaucher disease, and it demonstrates that there is significant phenotypic and genotypic heterogeneity among patients with type 2 Gaucher disease. Hum Mutat 15:181-188, 2000. Published 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10649495     DOI: 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  68 in total

1.  Perinatal lethal Gaucher disease.

Authors:  Nishad Plakkal; Amuchou Singh Soraisham; Junya Jirapradittha; Alfredo Pinto-Rojas
Journal:  Indian J Pediatr       Date:  2010-10-06       Impact factor: 1.967

2.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.

Authors:  Samarjit Patnaik; Wei Zheng; Jae H Choi; Omid Motabar; Noel Southall; Wendy Westbroek; Wendy A Lea; Arash Velayati; Ehud Goldin; Ellen Sidransky; William Leister; Juan J Marugan
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

3.  Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

Authors:  Zhanqian Yu; Anu R Sawkar; Lisa J Whalen; Chi-Huey Wong; Jeffery W Kelly
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

Review 4.  Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy.

Authors:  B Segarane; A Li; R Paudel; S Scholz; J Neumann; A Lees; T Revesz; J Hardy; C J Mathias; N W Wood; J Holton; H Houlden
Journal:  Neurology       Date:  2009-03-31       Impact factor: 9.910

5.  Four Gaucher disease type II patients with three novel mutations: a single centre experience from Turkey.

Authors:  Fatma Derya Bulut; Deniz Kör; Berna Şeker-Yılmaz; Özlem Hergüner; Serdar Ceylaner; Ferda Özkınay; Sebile Kılavuz; Neslihan Önenli-Mungan
Journal:  Metab Brain Dis       Date:  2018-04-14       Impact factor: 3.584

6.  Identification of recombinant alleles using quantitative real-time PCR implications for Gaucher disease.

Authors:  Arash Velayati; Melanie A Knight; Barbara K Stubblefield; Ellen Sidransky; Nahid Tayebi
Journal:  J Mol Diagn       Date:  2011-07       Impact factor: 5.568

7.  Gaucher disease type 2: homozygosity for the mutation F331S in two unrelated consanguineous Muslim Arab patients with Gaucher disease from the Gaza and Jenin regions.

Authors:  Hagit N Baris; Annick Raas-Rothschild; Ben-Zion Garty; Ruth Tor; Sarah Klontz; Nahid Tayebi; Ellen Sidransky; Ian J Cohen
Journal:  Blood Cells Mol Dis       Date:  2011-09-01       Impact factor: 3.039

Review 8.  The clinical management of Type 2 Gaucher disease.

Authors:  Karin Weiss; Ashley Gonzalez; Grisel Lopez; Leah Pedoeim; Catherine Groden; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2014-11-14       Impact factor: 4.797

9.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

10.  Glucosidase-beta variations and Lewy body disorders.

Authors:  Matthew J Farrer; Lindsey N Williams; Avi A Algom; Jennifer Kachergus; Mary M Hulihan; Owen A Ross; Alex Rajput; Spiridon Papapetropoulos; Deborah C Mash; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2008-10-01       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.